Cyclacel PharmaceuticalsCYCC
Market Cap: $2.01M
About: Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Employees: 12
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
192% more capital invested
Capital invested by funds: $127K [Q1] → $371K (+$244K) [Q2]
33% more funds holding
Funds holding: 12 [Q1] → 16 (+4) [Q2]
11.11% more ownership
Funds ownership: 4.6% [Q1] → 15.71% (+11.11%) [Q2]
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for CYCC.
Financial journalist opinion
Based on 3 articles about CYCC published over the past 30 days